Global Antivenom Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antivenom Drugs Market Research Report 2024
Antivenom drugs are used to treat venomous bites and stings, usually preferable in high-toxicity cases. Antivenin, venom antiserum, and antivenom immunoglobulin are the different other names of antivenom drugs. These medications can potentially reverse the effects of snake bites, and generally, an adequate therapeutic dose is injected. Additionally, these medications also help in kidney dialysis, artificial respiration, prosthesis as well as rehabilitation services.
According to Mr Accuracy reports’s new survey, global Antivenom Drugs market is projected to reach US$ 1384.7 million in 2029, increasing from US$ 1096 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antivenom Drugs market research.
There are more than 3,000 species of snakes in the world, of which about 250 are prioritized by the WHO because of the potential for serious injury from their venom, spread across 160 countries around the world, the WHO said. Snakebites mainly occur in developing countries in tropical and subtropical regions. Sub-Saharan Africa, tropical Asia, New Guinea, and central and southern America are all high incidence areas of snakebite. In India alone, as many as 2.8 million people are bitten by snakes every year, and more than 46,000 of them die. Rising number of people bitten by snakes is the key driver for the growth of the antivenom market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antivenom Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bioclone Institute
Pfizer Inc
Merck KGaA
VINS Bioproducts Ltd
BTG International Inc
Incepta Pharma
Bharat Serums and Vaccines Limited
Boston Scientific Corporation
Alomone Labs
Wyeth, LLC
Serum Biotech
Segment by Type
Monovalent
Polyvalent
Hospital
Clinical Laboratory
Field Rescue Station
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antivenom Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Antivenom Drugs market is projected to reach US$ 1384.7 million in 2029, increasing from US$ 1096 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antivenom Drugs market research.
There are more than 3,000 species of snakes in the world, of which about 250 are prioritized by the WHO because of the potential for serious injury from their venom, spread across 160 countries around the world, the WHO said. Snakebites mainly occur in developing countries in tropical and subtropical regions. Sub-Saharan Africa, tropical Asia, New Guinea, and central and southern America are all high incidence areas of snakebite. In India alone, as many as 2.8 million people are bitten by snakes every year, and more than 46,000 of them die. Rising number of people bitten by snakes is the key driver for the growth of the antivenom market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antivenom Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bioclone Institute
Pfizer Inc
Merck KGaA
VINS Bioproducts Ltd
BTG International Inc
Incepta Pharma
Bharat Serums and Vaccines Limited
Boston Scientific Corporation
Alomone Labs
Wyeth, LLC
Serum Biotech
Segment by Type
Monovalent
Polyvalent
Segment by Application
Hospital
Clinical Laboratory
Field Rescue Station
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antivenom Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices